Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand.

ABSTRACT:

Importance

Randomized clinical trials in prostate cancer have reported noninferior outcomes for hypofractionated radiation therapy (HRT) compared with conventional RT (CRT); however, uptake of HRT across jurisdictions is variable.

Objective

To evaluate the use of HRT vs CRT in men with nonmetastatic prostate cancer and compare patient-reported outcomes (PROs) at a population level.

Design, setting, and participants

Registry-based cohort study from the Australian and New Zealand Prostate Cancer Outcomes Registry (PCOR-ANZ). Participants were men with nonmetastatic prostate cancer treated with primary RT (excluding brachytherapy) from January 2016 to December 2019. Data were analyzed in March 2021.

Exposures

HRT defined as 2.5 to 3.3 Gy and CRT defined as 1.7 to

SUBMITTER: Pryor DI 

PROVIDER: S-EPMC8561328 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature